SAN DIEGO , May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trial ANB020-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33 loss-of-function studies Favorable safety, pharmacokinetics and pharmacodynamics observed in

Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitis and Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of 2018 SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.

SAN DIEGO , May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that clinical data for its ANB020 and ANB019 programs will be

SAN DIEGO , April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that that company will participate in the following investor

46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with placebo Concomitant allergy symptoms, typically overlapping with peanut allergy, occurred in 80% of

ANB020 Top-Line Phase 2a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018 ANB019 GPP and PPP Phase 2 Studies to be Initiated During 2018 SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.

SAN DIEGO , Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial of ANB020,

SAN DIEGO , Feb. 07, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that data from the company’s Phase 2a trial of ANB020,

SAN DIEGO , Jan. 02, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will